GlassScriptPhysician profile
Neelam Gupta
NPI 1942289731
$19,645.27
in general payments reported to CMS, 2019-2025
55 companies · $2,087 in 2025
The $2,087 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,993 · 2020: $1,839 · 2021: $3,372 · 2022: $3,656 · 2023: $2,006 · 2024: $2,692 · 2025: $2,087.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,784.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,836.14 | 2019-2025 | |
| Amgen INC. | $1,318.69 | 2019-2025 | Repatha, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,216.00 | 2019-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $1,097.89 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $973.44 | 2019-2024 | Farxiga, Lokelma |
| Pfizer INC. | $887.83 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $851.70 | 2020-2023 | |
| Evoke Pharma, INC. | $750.78 | 2022-2024 | Gimoti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $743.00 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $721.79 | 2019-2023 | |
| Redhill Biopharma INC. | $676.95 | 2020-2024 | Talicia, Aemcolo, Movantik |
| Janssen Biotech, INC. | $661.86 | 2022-2025 | Tremfya, Stelara |
| Novo Nordisk INC | $568.63 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Mallinckrodt Hospital Products INC. | $465.21 | 2020-2023 | Acthar |
| Olympus America INC. | $463.93 | 2019 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neelam Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.